期刊
EXPERT REVIEW OF CLINICAL PHARMACOLOGY
卷 7, 期 3, 页码 281-291出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/17512433.2014.893819
关键词
bazedoxifene; estrogen; menopause; osteoporosis; vasomotor symptoms
资金
- Amgen
- Merck
- Eli Lilly
- Pfizer
Menopausal therapy with a tissue selective estrogen complex combines estrogens with a selective estrogen receptor modulator, with the goal of blending the desirable effects of estrogens on menopausal symptoms and bone with the tissue selective properties of a selective estrogen receptor modulator. The first tissue selective estrogen complex to receive regulatory approval is a combination of conjugated estrogens (CE) with bazedoxifene (BZA). Clinical trials with CE/BZA in postmenopausal women have shown improvement in vasomotor symptoms, vulvo-vaginal atrophy, and bone mineral density, without stimulation of the endometrium or breast tissue, with a generally favorable safety and tolerability profile. CE/BZA represents a new approach to the management of menopausal symptoms in women with a uterus.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据